Title The plasma level of mCRP is linked to cardiovascular disease in antineutrophil cytoplasmic antibody-associated vasculitis

Running Title Relationship between mCRP and cardiovascular disease in AAV

Authors Kai-Li Wu\textsuperscript{ab}; Qing-Hui Liang\textsuperscript{b#}; Bin-Tao Huang\textsuperscript{a}; Na Ding\textsuperscript{ab}; Bo-Wei Li\textsuperscript{ab}; Jian Hao, MD\textsuperscript{a}

Institutes \textsuperscript{a}Renal Division, Department of Medicine; The Affiliated Hospital of Inner Mongolia Medical University, Huhehot, Inner Mongolia 010050, China

\textsuperscript{b}Inner Mongolia Medical University, Huhehot, Inner Mongolia 010059, China

Correspondence: Jian Hao

Renal Division, Department of Medicine, The Affiliated Hospital of Inner Mongolia Medical University;

Huhehot, Inner Mongolia 010050, China

Telephone: +86-13704751021

mail: jian_hao8865@163.com

\# Kai-Li Wu and Qing-Hui Liang contributed equally to this work
Abstract

[Background] C-reactive protein (CRP) has two natural isomers: C-reactive protein pentamer (pCRP) and C-reactive protein monomer (mCRP). The levels of CRP are significantly elevated in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). mCRP not only activates the endothelial cells, platelets, leukocytes, and complements, but also has a proinflammatory structural subtype that can localize and deposit in inflammatory tissues. Thus, it regulates a variety of clinical diseases, such as ischemia/reperfusion (I/R) injury, Alzheimer’s disease, age-related macular degeneration, and cardiovascular disease. We hypothesized that plasma mCRP levels are related to cardiovascular disease in AAV.

[Methods] In this cross-sectional study, 37 patients with AAV were assessed. Brain natriuretic peptide (BNP) and mCRP in plasma were assessed by enzyme-linked immunosorbent assay (ELISA). The acute ST-segment elevation myocardial infarction (STEMI) was diagnosed by coronary angiography, and the Gensini score calculated. Echocardiography evaluated the ejection fraction (EF%), left ventricular end-diastolic volume (LVEDV), left ventricular end-systolic volume (LVESV), and left ventricular mass index (LVMI). Estimated glomerular filtration rate (eGFR) was calculated based on serum creatinine, age, and gender. [Results] The plasma level of mCRP in AAV was significantly higher than that in healthy volunteers ($P<0.001$). Then, mCRP and CRP levels were compared with and without STEMI complications in AAV. The plasma level of mCRP was higher, but that of CRP was lower in STEMI.
The plasma level of mCRP was correlated with Birmingham vasculitis activity score (BVAS), eGFR, BNP, EF%, LVEDV, LVESV, LVMI, and STEMI complications’ Gensini score in AAV; however, CRP did not correlate with BNP, EF%, LVEDV, LVESV, LVMI, and Gensini score.

[Conclusions] The plasma level of mCRP was related to cardiovascular diseases in AAV patients.

[Keywords] mCRP, AAV, cardiovascular diseases, eGFR
Introduction

Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is commonly characterized by a small amount of immunoglobulin deposition and segmental vascular wall necrotic inflammation [1]. AAV patients are classified into granulomas with polyangiitis (GPA), eosinophilic granulomas with polyangiitis (EGPA), and microvascular polyangiitis (MPA), according to pathological and clinical characteristics [2]. Target antigens for AAV diseases include protease 3 (PR3) and myeloperoxidase (MPO) [3,4]. The majority of the Chinese patients with AAV are positive for MPO ANCA [5-7], which activates and damages glomerular endothelial cells (GEnC) in patients with AAV [7-9].

C-reactive protein (CRP) is an acute-phase protein that serves as an inflammatory response biomarker [10,11]. During activity and relapse of AAV disease, serum CRP levels increase rapidly, followed by a decrease during remission of the disease [12,13]. Human CRP in blood circulation consists of C-reactive protein pentamer (pCRP) and tissue-related C-reactive protein monomer (mCRP) [14]. In atherosclerosis-related experiments in mice, CRP bound to the Fc receptor CD32, while mCRP bound to another human Fc receptor subtype CD16 in neutrophils and performed function that was opposite to that of CRP [15]. Thus, FC receptor may be the key that links CRP and mCRP to AAV.

The most common pathogenesis of ST-segment elevation myocardial infarction (STEMI) is atherosclerotic fragile plaque rupture and thrombus-induced cardiac
muscle cell necrosis. Also, inflammatory reactions are crucial responses [16,17]. CRP is involved in acute myocardial infarction. mCRP is obtained from the dissociation process of necrobiosis. Moreover, mCRP explains the function of CRP, while pCRP does not promote inflammation [18]. In vitro tests have shown that mCRP induces the synthesis of neutrophil-derived chemokines, stimulates the expression of monocyte integrin [19], and promotes neutrophil adhesion to vascular endothelial cells [20].

CRP is the classical acute-phase protein named for its ability to precipitate and bind to the pneumococcal C-polysaccharide. Although the blood circulation concentration is low in healthy individuals, the level of CRP increases sharply when tissue damage and inflammation occur [21,22]. Currently, CRP is used not only as a marker of inflammation but also as a crucial and independent predictor of atherosclerotic thrombosis (including cardiovascular events) [22].

Active AAV patients have high levels of CRP [13,23]. Also, renal involvement is common in patients with AAV, including renal tubulointerstitial (TI) lesions [24,25]. mCRP is an acute-phase protein in the tissues or cells and may be an antigen in the acute tubulointerstitial (ATIN) [25]. Serum CRP is decomposed into mCRP and induces the generation of free oxygen radicals on the surface of apoptotic and necrotic cells, resulting in inflammatory reactions [26]. It was also found that mCRP is not only related to thrombosis [27] and atherosclerotic plaque rupture but can also be concentrated in localized areas after transient myocardial ischemia and related to
acute myocardial infarction (AMI) [28]. Therefore, we hypothesized that plasma mCRP levels are related to cardiovascular disease in AAV.

Methods

Collecting plasma samples

This cross-sectional study utilized plasma samples collected from 37 patients with AAV and 20 healthy volunteers. The AAV patients were diagnosed in the Department of Nephrology, Affiliated Hospital of Inner Mongolia Medical University, from October 2018 to November 2019. The patients met the criteria set at the Chapel Hill Consensus Meeting [29]. All the participants provided informed consent. Subjects with other autoimmune diseases, such as IgA nephropathy, rheumatoid arthritis, Graves’ disease, and lupus nephritis, as well as secondary and various acute infectious vasculitis, were excluded. A volume of 5 mL venous blood from each patient was withdrawn and collected in EDTA anticoagulation tubes within 24h of admission. The supernatant was separated by centrifugation at 3000 rpm, 10 min and stored at -80 °C for subsequent use. Repeated freeze-thaw cycles are prohibited for this sample. The disease activity was based on the Birmingham vasculitis activity score (BVAS) in AAV patients [30]. The study was approved by the Ethics Committee of the Helsinki Declaration of Inner Mongolia Medical University.

Detection of mCRP by enzyme-linked immunosorbent assay (ELISA)
Plasma mCRP levels were tested by ELISA using a commercial kit (Kamaishu Biotechnology Co, Shanghai, China). The 96-well plate was coated with mCRP and blocked to reduce non-specific binding. Antibodies compete for binding to a plate or sample. This kit uses the double antibody sandwich method to determine the level of human mCRP in the specimen. The microtiter plates were coated with purified human mCRP antibodies to make solid-phase antibodies. Then, mCRP was added to the microwells, followed by the addition of HRP-labeled mCRP antibodies to form an antibody-antigen complex, as assessed by ELISA. Subsequently, the substrate tetramethylbenzidine (TMB) was used to develop the color. The absorbance (OD value) of the colored complex was measured at 450 nm, and the human mCRP concentration in the sample was calculated by a standard curve [31].

**Detection of brain natriuretic peptide (BNP) by ELISA**

BNP was detected by a double-antibody sandwich immunoenzyme method, using Unicel-TM-DXI800 (Beckman, CA, USA) full-automated immunoassay instrument. The ELISA was performed, as described previously [32].

**Detection of circulating blood serum creatinine (Scr), estimated glomerular filtration rate (eGFR), and CRP**

Scr was determined by a rating method using a commercial kit (Beckman, CA, USA) [33]. The level of CRP was determined by immunoturbidimetry using a commercially available kit (Goldsite, Shenzhen, China) [34]. According to Scr, age, and gender, the eGFR of the patient was calculated. The modification of diet in renal disease (MDRD)
formula was adapted by Chinese experts. The female eGFR calculation formula was as follows: eGFR(mL/min/1.73m$^2$)=186×Scr-1.154×(age)-0.203×0.742×1.227 and male eGFR calculation formula
eGFR(mL/min/1.73m$^2$)=186×Scr-1.154×(age)-0.203×1.227 [35]

**Detection of ejection fraction (EF%), left ventricular end-diastolic volume (LVEDV), left ventricular end-systolic volume (LVESV), and left ventricular mass index (LVMI)**

The values of EF%, LVEDV, LVESV, left ventricular septal end-diastolic thickness (IVSTD), and left ventricular posterior wall diastolic thickness (LVPWTD) were obtained by echocardiography. Then, the value of left ventricular myocardial mass (LVM) was calculated based on LVIDD, IVSTD, and LVPWTD. Body surface area (BSA) was calculated through weight (W) and height (H).

LVM (g) =1.04 { [(LVIDD + PWTD + IVSTD)$^3$ - (LVIDD)$^3$] - 13.6}

BSA (m$^2$) = (W$^{0.425}$×H$^{0.725}$) × 0.007184 [36]

**Statistical analysis**

All data were statistically analyzed using SPSS19.0. All grouped data were tested for normality before further analysis. The two groups of enumeration data that conformed to the normal distribution were compared using an independent t-test. If any of the groups did not match, a non-parametric rank-sum test was used. If the data fulfilled the normal distribution, it would be expressed as means ( $\bar{x}$ ) ± standard deviation
(SD). Used the Shapiro-Wilk test, median and interquartile range (IQR) checked the degree of dispersion of the data. The correlation between the two groups of data were analyzed, if both groups met the normal distribution, Pearson’s rank correlation was used, and if any group did not meet the normal distribution, Spearman’s rank correlation was utilized. Cross-tabulation χ² test for gender comparison. P<0.05 indicated statistical significance.

Results

General data from AAV patients and healthy volunteers (normal control)

A total of 37 AAV patients were MPO-ANCA, including 17 (45.9%) females and 20 (54.1%) males. Among the 4 AAV patients with STEMI complications, 2 (50.0%) were males and 2 (50.0%) were females, with average age 59.5±14.3 years, while that of the 37 AAV patients was 58.5±10.6 years. The healthy volunteers consisted of 10 (50.0%) males and 10 (50.0%) females, aged 55.3±10.7 years. The comparison of age and sex between 37 AAV patient groups and healthy volunteers (n=20, P=0.266; n=20, P=0.788) did not show significant differences. Next, we used the same method to compare the age and gender of 4 patients with STEMI complications and 33 patients without STEMI complications in the AAV group. Therefore, both the AAV patient group and the normal control, as well as patients with and without STEMI complications in the AAV group showed no significant difference in the age and sex (P>0.05). Also, the relevant biochemical indicators were analyzed in AAV patients (Table 1).
Correlation between mCRP and cardiovascular disease risk factors

Status, age, and gender are unmodifiable factors with respect to the risk of cardiovascular diseases, while modifiable factors include tobacco, alcohol, hypertension, diabetes, and obesity. Moreover, the correlation between clinical indicators of cardiovascular risk factors (lipid- and inflammation-related factors) and mCRP were compared. We found that mCRP was negatively correlated with total cholesterol (TG) and CRP ($r=-0.592$, $P<0.001$; $r=-0.340$, $P=0.040$, respectively), (Table 2).

Plasma levels of mCRP were higher in AAV patients than in normal controls

The plasma levels of mCRP in AAV patients was 244.1 (226.1, 331.7) μg/mL and that in the normal control was 170.0 (135.7, 199.3) μg/mL. Next, we compared the plasma levels of mCRP in AAV patients and healthy volunteers ($P<0.001$) and found significant differences (Figure 1).

Plasma levels of mCRP were highest in patients with than in those without STEMI complications

The AAV patients were divided into groups with ($n=4$) and without STEMI complications ($n=33$) groups (Figure 2A). The plasma concentration of mCRP in patients with and without STEMI complications in AAV group was 581.4 (508.7, 647.3) and 240.8 (219.2, 292.1) μg/mL, respectively, while that in normal controls was 170.0 (135.7, 199.3) μg/mL (Figure 2B). We also compared the BVAS of
patients with and without STEMI complications (Figure 2C).

**Plasma levels of mCRP were positively correlated with BVAS and Scr and negatively correlated with eGFR**

BVAS in 37 AAV patients and normal controls was 29.9±9.1 and 0, while Scr was 291.0 (161.5, 434.5), respectively. The eGFR was calculated based on gender, age, and Scr levels. The eGFR was 17.7 (10.1, 41.0) mL/min/1.73m² in AAV patients and 170.0 (135.7, 199.3) mL/min/1.73m² in normal controls. Thus, we analyzed the correlation between mCRP and BVAS \((r=0.404, P=0.013, \text{Figure 3A})\), mCRP and eGFR \((r=-0.341, P=0.039, \text{Figure 3B})\).

**Plasma levels of mCRP were correlated with BNP, EF%, LVEDV, LVESV, LVMI, and STEMI complications’ Gensini score, but not CRP**

The Gensini score of patients with STEMI complications in AAV was 72.0±15.1. The BNP level in circulating blood was 155.7 (104.4, 204.3) pg/mL, while the EF (%) levels were 63.0±8.8 %, LVEDV was 124.2±25.3 mL, LVESV was 44.2±10.7 mL, LVMI was 86.5 (50.6, 112.6), and the Gensini score of four STEMI complications was 72.0±15.1 in AAV patients.

Furthermore, we speculated that the plasma levels of mCRP might be related to the patient’s heart disease, and hence, the correlation between mCRP and BNP, EF%, LVEDV, LVESV, LVMI, and Gensini score of STEMI complications was analyzed \((r=0.349, P=0.034 \text{ Figure 4A}; r=-0.362, P=0.027 \text{ Figure 4B}; r=0.375, P=0.022)\).
Figure 4C, $r=0.334$, $P=0.043$ Figure 4D; $r=0.736$, $P<0.001$ Figure 4E; $r=0.997$, $P=0.023$ Figure 4F, respectively), while CRP was not correlated (Table 3).

Discussion

Accumulating evidence has shown that CRP is pathogenic in atherosclerosis, acute myocardial infarction, cerebral infarction, and AAV disease [37]. CRP is one of the biomarkers for assessing AAV disease activity. The serum CRP concentration increased during the AAV active phase and decreased rapidly with the remission of the disease [13,38]. mCRP can bind with complement factor H (CFH) and is more effective than pCRP in inhibiting alternative complement [39] and plays a critical role in the development of AAV [40,41]. Xu et al. showed that MPO inhibits the binding between CFH and mCRP, thereby inhibiting the regulatory activation of alternative complements. PR3 does not bind to either pCRP or mCRP, while MPO can bind to mCRP, which blocks the binding between mCRP and CFH [41]. Therefore, the mechanism of mCRP and AAV disease is indistinguishable.

CRP can be decomposed into mCRP at high temperature, urea, or acidic microenvironment [42,43]. mCRP activates platelets [20], monocytes [44], and endothelial cells [45]. It is a key substance that promotes inflammatory response [21,46]. The mechanism underlying the inflammatory response of endothelial cells is caused by the interaction of mCRP with neutrophils, macrophages, and platelets [46,47]. Furthermore, mCRP binds to CFH and directs it to the damaged part of the cell [48,49], inactivates C3b, and limits the progression of inflammation [39].

12
Therefore, we speculated that the role of mCRP in the pathogenesis of AAV disease might be related to CFH.

In patients with lupus, the level of anti-mCRP autoantibodies is related to the degree of renal interstitial lesions [50], and mCRP has been reported as an autoantigen in interstitial nephritis-associated uveitis (TINU) syndrome [51]. In AAV patients, anti-mCRP antibodies may be the cause of severe TI lesions [25].

Serum CRP levels increase due to acute infection, trauma, and inflammation [52]. Thus, CRP is commonly used for the risk stratification of cardiovascular disease [53,54], as well as a marker of generalized atherosclerosis [54,55]. CRP levels are significantly increased in cardiovascular patients without any symptoms, obvious cardiovascular disease, unstable angina pectoris, myocardial infarction, and other diseases [22,56]. Also, it is directly involved in the response process of acute myocardial infarction [18]. Thielle et al. demonstrated that mCRP stimulates inflammation, while pCRP has no proinflammatory effect [45]. In addition, Diehl et al. detected mCRP deposition in human atherosclerotic plaque vessels [57]. Similarly, studies on cardiovascular disease have found that mCRP is present in endothelial cells cultured in vitro and can promote inflammatory responses [20]. In the current study, 37 patients with AAV were collected and 4 patients with STEMI complications were found.

mCRP has lectin-like properties and can bind galactose-containing residues [12,58,59]. ANCA-induced NETs activate the platelets and then promote mCRP
formation on these platelets. Subsequently, the newly generated mCRP can further enhance thrombosis and inflammatory response during platelet activation. mCRP may be a potential link between thrombosis and inflammation in AAV. Therefore, we suspected that the occurrence of STEMI complications in patients was related to mCRP [12]. AAV exhibits various echocardiographic characteristics, such as decreased systolic function, increased diastolic dysfunction, and pulmonary hypertension at the time of diagnosis [60]. The current study focused on cardiovascular disease in patients with AAV, which reflected the clinical examination of cardiovascular function by echocardiography. EF%, LVEDV, and LVESV are indicators of heart function. LVMI is associated with the mortality of patients with chronic kidney disease (CKD) and is a high-risk factor of heart failure [61]. Therefore, we analyzed the correlation between EF%, LVEDV, LVESV, LVMI, and mCRP. In this study, we proved that circulating blood levels of CRP were significantly higher in AAV patients than healthy volunteers. Also, mCRP levels, but not CRP levels, were significantly increased in patients with STEMI complications. Next, we analyzed the correlation between mCRP levels and the Gensini score of STEMI complications and that between mCRP levels, BNP, and EF% in patients with AAV and found that the level of mCRP was positively correlated with the Gensini score and BNP and negatively correlated with EF%.

Nevertheless, the present study had some limitations. First, it was not a longitudinal study because while collecting cardiovascular clinical indicators, a large amount of
experimental data were collected first, followed by comparison analysis. Finally, it was found that the mCRP level was related to the different parameters mentioned in this study. However, AAV patients have low morbidity but high mortality [12]. Most AAV patients visit our department for treatment due to abnormal renal function. The patients we collected in this study were MPO-ANCA because it is a predominant condition in Chinese AAV patients [14,17]. Therefore, follow-up studies are imperative.

Conclusions

The level of mCRP is related not only to AAV disease but also to the occurrence of cardiovascular disease in patients with AAV. Therefore, mCRP can be used as a plasma biomarker of cardiovascular diseases in AAV.

Abbreviations

CRP: C-reactive protein; pCRP: C-reactive protein pentamer; mCRP: C-reactive protein monomer; ANCA: Anti-neutrophil cytoplasmic antibody; AAV: Anti-neutrophil cytoplasmic antibody-associated vasculitis; PR3: Protease 3; MPO: Myeloperoxidase; Scr: Serum creatinine; Hb: Hemoglobin; PTH: Parathyroid hormone; CTnT: Cardiac troponin T; CK: Creatine kinase; CK-MB: Creatine kinase isoenzyme; HDL-C: high-density lipoprotein; Tch: Total serum cholesterol; TG: Triglyceride; LDL-C: Low-density lipoprotein; Fib: Fibrinogen; ELISA: TMB: the substrate tetramethylbenzidine; enzyme-linked immunosorbent assay; BNP: Brain natriuretic peptide; STEMI: ST-segment elevation myocardial infarction; EF%:
Ejection fraction; LVEDV: Left ventricular end-diastolic volume; LVESV: Left ventricular end-systolic volume; LVMI: Left ventricular mass index; AMI: Acute myocardial infarction; LVIDD: Left ventricular end-diastolic diameter; IVSTD: Left ventricular septal end-diastolic thickness; LVPWTD: Left ventricular posterior wall diastolic thickness; LVM: Left ventricular myocardial mass; GEnC: Glomerular endothelial cells; TI: Tubulointerstitial; ATIN: Acute tubulointerstitial; eGFR: Glomerular filtration rate; BVAS: Birmingham vasculitis activity score;

**Ethics approval and consent to participate**

All patients provided their informed written consent. The study was approved by the Ethics Committee of the Helsinki Declaration of Inner Mongolia Medical University.

**Consent for publication**

Not applicable

**Availability of data and materials**

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Competing interests**

The authors declare that they have no competing interests.

**Funding**

The two funds are the China Natural Science Foundation (NO81460145) and Inner
Mongolia Natural Science Foundation Project Number (2018MS08105).

Authors’ contributions

Kai-Li Wu and Qing-Hui Liang conducted experiments, analyzed the data and drafted the manuscript. Na Ding and Bo-Wei Li conducted experiments. Bin-Tao Huang participated in revise manuscript. Jian Hao conceived the study and participated in the Revise manuscript and provide final approval to submit the version of the document. All authors read, and the report was approved.

Acknowledgements

The Affiliated Hospital of Inner Mongolia Medical University; Funding details are included above.

Authors’ information

aRenal Division, Department of Medicine; The Affiliated Hospital of Inner Mongolia Medical University, Huhehot, Inner Mongolia 010050, China; bInner Mongolia Medical University, Huhehot, Inner Mongolia 010059, China.

References

1. Jennette JC, Falk RJ. Small-vessel vasculitis. New England Journal of Medicine. 1997;337(21):1512-1523.
2. Jennette JC, Falk R, Bacon P, et al. 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis & Rheumatism. 2013;65(1):1-11.

3. Segelmark M, Wieslander J. IgG subclasses of antineutrophil cytoplasm autoantibodies (ANCA). Nephrology Dialysis Transplantation. 1993;8(8):696-702.

4. Hao J, Huang Y-M, Zhao M-H, Chen M. The interaction between C5a and sphingosine-1-phosphate in neutrophils for antineutrophil cytoplasmic antibody mediated activation. Arthritis research & therapy. 2014;16(4):R142.

5. Chen M, Yu F, Zhang Y, Zou W-Z, Zhao M-H, Wang H-Y. Characteristics of Chinese patients with Wegener's granulomatosis with anti-myeloperoxidase autoantibodies. Kidney international. 2005;68(5):2225-2229.

6. Li ZY, Chang DY, Zhao MH, Chen M. Predictors of treatment resistance and relapse in Antineutrophil Cytoplasmic antibody–associated Vasculitis: a study of 439 cases in a single Chinese center. Arthritis & rheumatology. 2014;66(7):1920-1926.

7. Sun X-J, Chen M, Zhao M-H. Thrombin contributes to anti-myeloperoxidase antibody positive IgG-mediated glomerular endothelial cells activation through SphK1-S1P-S1PR3 signaling. Frontiers in immunology. 2019;10:237.
8. Nagao T, Matsumura M, Mabuchi A, et al. Up-regulation of adhesion molecule expression in glomerular endothelial cells by anti-myeloperoxidase antibody. Nephrology Dialysis Transplantation. 2007;22(1):77-87.

9. Nagao T, Suzuki K, Utsunomiya K, et al. Direct activation of glomerular endothelial cells by anti-moesin activity of anti-myeloperoxidase antibody. Nephrology Dialysis Transplantation. 2011;26(9):2752-2760.

10. Ten Oever J, Netea MG, Kullberg B-J. Utility of immune response-derived biomarkers in the differential diagnosis of inflammatory disorders. Journal of Infection. 2016;72(1):1-18.

11. Coster D, Wasserman A, Fisher E, et al. Using the kinetics of C-reactive protein response to improve the differential diagnosis between acute bacterial and viral infections. Infection. 2019:1-8.

12. Xu P-c, Lin S, Yang X-w, et al. C-reactive protein enhances activation of coagulation system and inflammatory response through dissociating into monomeric form in antineutrophil cytoplasmic antibody-associated vasculitis. BMC Immunology. 2015;16(1):10.

13. Kälsch A-I, Csernok E, Münch D, et al. Use of highly sensitive C-reactive protein for followup of Wegener’s granulomatosis. The Journal of rheumatology. 2010;37(11):2319-2325.
14. Shrive AK, Cheetham GM, Holden D, et al. Three dimensional structure of human C-reactive protein. Nature structural biology. 1996;3(4):346-354.

15. Yeh ET. A new perspective on the biology of C-reactive protein. Am Heart Assoc; 2005.

16. Nakajima T, Yamazaki K. Periodontal disease and risk of atherosclerotic coronary heart disease. Odontology. 2009;97(2):84-91.

17. Papathanasiou AI, Pappas KD, Korantzopoulos P, et al. An epidemiologic study of acute coronary syndromes in northwestern Greece. Angiology. 2004;55(2):187-194.

18. Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. Journal of the American College of Cardiology. 2007;49(21):2129-2138.

19. Khreiss T, József L, Potempa LA, Filep JG. Loss of pentameric symmetry in C-reactive protein induces interleukin-8 secretion through peroxynitrite signaling in human neutrophils. Circulation research. 2005;97(7):690-697.

20. Eisenhardt SU, Habersberger J, Murphy A, et al. Dissociation of pentameric to monomeric C-reactive protein on activated platelets localizes inflammation to atherosclerotic plaques. Circulation research. 2009;105(2):128-137.
21. Wu Y, Potempa LA, El Kebir D, Filep JG. C-reactive protein and inflammation: conformational changes affect function. Biological chemistry. 2015;396(11):1181-1197.

22. Boncler M, Wu Y, Watala C. The Multiple Faces of C-Reactive Protein—Physiological and Pathophysiological Implications in Cardiovascular Disease. Molecules. 2019;24(11):2062.

23. Chen S-F, Wang F-M, Li Z-Y, Yu F, Chen M, Zhao M-H. The functional activities of complement factor H are impaired in patients with ANCA-positive vasculitis. Clinical Immunology. 2017;175:41-50.

24. Zonozi R, Niles JL, Cortazar FB. Renal Involvement in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. Rheumatic Disease Clinics. 2018;44(4):525-543.

25. Lin Z-S, Liu X-L, Cui Z, et al. Acute tubulointerstitial nephritis with germinal centers in antineutrophil cytoplasmic antibody-associated vasculitis: A case report and literature review. Medicine. 2019;98(48):e18178.

26. Wang H-W, Sui S-f. Dissociation and subunit rearrangement of membrane-bound human C-reactive proteins. Biochemical and biophysical research communications. 2001;288(1):75-79.
27. Molins B, Peña E, de la Torre R, Badimon L. Monomeric C-reactive protein is prothrombotic and dissociates from circulating pentameric C-reactive protein on adhered activated platelets under flow. Cardiovascular Research. 2011;92(2):328-337.

28. Wang J, Tang B, Liu X, et al. Increased monomeric CRP levels in acute myocardial infarction: A possible new and specific biomarker for diagnosis and severity assessment of disease. Atherosclerosis. 2015;239(2):343-349.

29. Schreiber A, Xiao H, Jennette JC, Schneider W, Luft FC, Kettritz R. C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. Journal of the American Society of Nephrology. 2009;20(2):289-298.

30. Luqmani R, Bacon P, Moots R, et al. Birmingham vasculitis activity score (BVAS) Dim system necrotizing vasculitis. QJM: An International Journal of Medicine. 1994;87(11):671-678.

31. Tan Y, Yu F, Qu Z, et al. Modified C-reactive protein might be a target autoantigen of TINU syndrome. Clinical Journal of the American Society of Nephrology. 2011;6(1):93-100.

32. Mayo D, Colletti JE, Kuo D. Brain natriuretic peptide (BNP) testing in the emergency department. Journal of Emergency Medicine. 2006;31(2):201-210.

33. Organization WH. Use of anticoagulants in diagnostic laboratory investigations. World Health Organization;2002.
34. Rosen M. C-reactive protein: a marker of infection, inflammation, tissue damage and malignancy. Diag Clin Testing. 1990;28:18-22.

35. Ma Y-C, Zuo L, Chen J-H, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. Journal of the American Society of Nephrology. 2006;17(10):2937-2944.

36. Shaimaa, Ahmed, Mostfa. Impact of obesity and surgical weight reduction on cardiac remodeling. Indian Heart Journal. 2018.

37. Gill R, Kemp JA, Sabin C, Pepys MB. Human C-reactive protein increases cerebral infarct size after middle cerebral artery occlusion in adult rats. Journal of Cerebral Blood Flow & Metabolism. 2004;24(11):1214-1218.

38. Xu P-c, Hao J, Yang X-w, Chang D-y, Chen M, Zhao M-h. C-reactive protein enhances the respiratory burst of neutrophils-induced by antineutrophil cytoplasmic antibody. Molecular immunology. 2012;52(3-4):148-154.

39. Mihlan M, Blom AM, Kupreishvili K, et al. Monomeric C-reactive protein modulates classic complement activation on necrotic cells. The FASEB Journal. 2011;25(12):4198-4210.

40. Hao J, Meng L-Q, Xu P-C, Chen M, Zhao M-H. p38MAPK, ERK and PI3K signaling pathways are involved in C5a-primed neutrophils for ANCA-mediated activation. PloS one. 2012;7(5).
41. Xu P-c, Li Z-y, Yang X-w, Zhao M-h, Chen M. Myeloperoxidase influences the complement regulatory function of modified C-reactive protein. Innate immunity. 2014;20(4):440-448.

42. Potempa LA, Maldonado BA, Laurent P, Zemel ES, Gewurz H. Antigenic, electrophoretic and binding alterations of human C-reactive protein modified selectively in the absence of calcium. Molecular immunology. 1983;20(11):1165-1175.

43. Kresl JJ, Potempa LA, Anderson BE. Conversion of native oligomeric to a modified monomeric form of human C-reactive protein. The international journal of biochemistry & cell biology. 1998;30(12):1415-1426.

44. Braig D, Nero TL, Koch H-G, et al. Transitional changes in the CRP structure lead to the exposure of proinflammatory binding sites. Nature communications. 2017;8(1):1-19.

45. Thiele JR, Habersberger J, Braig D, et al. Dissociation of pentameric to monomeric C-reactive protein localizes and aggravates inflammation: in vivo proof of a powerful proinflammatory mechanism and a new anti-inflammatory strategy. Circulation. 2014;130(1):35-50.

46. Caprio V, Badimon L, Di Napoli M, et al. pCRP-mCRP dissociation mechanisms as potential targets for the development of small-molecule anti-inflammatory chemotherapeutics. Frontiers in immunology. 2018;9:1089.
47. Eisenhardt SU, Thiele JR, Bannasch H, Stark GB, Peter K. C-reactive protein: how conformational changes influence inflammatory properties. Cell cycle. 2009;8(23):3885-3892.

48. Mihlan M, Stippa S, Józsi M, Zipfel P. Monomeric CRP contributes to complement control in fluid phase and on cellular surfaces and increases phagocytosis by recruiting factor H. Cell Death & Differentiation. 2009;16(12):1630-1640.

49. O'Flynn J, van der Pol P, Dixon KO, Prohószka Z, Daha MR, van Kooten C. Monomeric C-reactive protein inhibits renal cell-directed complement activation mediated by properdin. American Journal of Physiology-Renal Physiology. 2016;310(11):F1308-F1316.

50. Tan Y, Yu F, Yang H, Chen M, Fang Q, Zhao M-h. Autoantibodies against monomeric C-reactive protein in sera from patients with lupus nephritis are associated with disease activity and renal tubulointerstitial lesions. Human Immunology. 2008;69(12):0-844.

51. Tan Y, Yu F, Qu Z, Su T, Zhao MH. Modified C-Reactive Protein Might be a Target Autoantigen of TINU Syndrome. Clinical Journal of the American Society of Nephrology Cjasn. 2011;6(1):93-100.

52. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. The Journal of clinical investigation. 2003;111(12):1805-1812.
53. Ridker PM. A test in context: high-sensitivity C-reactive protein. Journal of the American College of Cardiology. 2016;67(6):712-723.

54. Li Y, Zhong X, Cheng G, et al. Hs-CRP and all-cause, cardiovascular, and cancer mortality risk: a meta-analysis. Atherosclerosis. 2017;259:75-82.

55. Elias-Smale SE, Kardys I, Oudkerk M, Hofman A, Witteman JC. C-reactive protein is related to extent and progression of coronary and extra-coronary atherosclerosis; results from the Rotterdam study. Atherosclerosis. 2007;195(2):e195-e202.

56. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107(3):363-369.

57. Diehl EE, Haines GK, Radosevich JA, Potempa LA. Immunohistochemical localization of modified C-reactive protein antigen in normal vascular tissue. The American journal of the medical sciences. 2000;319(2):79-83.

58. Lee RT, Lee YC. Carbohydrate ligands of human C-reactive protein: Binding of neoglycoproteins containing galactose-6-phosphate and galactose-terminated disaccharide. Glycoconjugate Journal. 2006;23(5-6):317-327.

59. Köttgen E, Hell B, Kage A, Tauber R. Lectin specificity and binding characteristics of human C-reactive protein. Journal of Immunology. 1992;149(2):445-453.
60. Ahn SS PE, Jung SM, Song JJ, Park YB, Lee SW. Echocardiographic features in patients with ANCA-associated vasculitis within 3 months before and after diagnosis. Clin Rheumatol. 2017;36(12):2751-2759.

61. Tripepi G, D'Arrigo G, Mallamaci F, et al. Prognostic values of left ventricular mass index in chronic kidney disease patients. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association. 2019.
Figure legends

Figure 1. Comparison of the plasma levels of mCRP in AAV patients \((n=37)\) and healthy volunteers \((n=20, P<0.001)\).

Figure 2. Plasma levels of mCRP were highest in STEMI complications in AAV than without STEMI complications in AAV and normal controls.

A. 37 AAV patients were divided into two groups: with STEMI complications \((n=4)\) and without STEMI complications \((n=33)\).

B. Plasma levels of mCRP in STEMI complications were highest in the three groups (with STEMI complications in AAV, without STEMI complications, normal).

C. Comparison of BVAS in groups with and without STEMI complications.

Figure 3. Plasma levels of mCRP were compared with BVAS and eGFR in AAV.

A. Correlation between mCRP and BVAS. The plasma levels of mCRP were positively correlated with BVAS \((r=0.404, P=0.013)\). BVAS, Birmingham vasculitis activity score.

B. Correlation between mCRP and eGFR. The plasma levels of mCRP were negatively correlated with eGFR \((r=-0.341, P=0.039)\). eGFR, estimated glomerular filtration rate.

Figure 4. Plasma levels of mCRP were correlated with BNP, EF%, LVEDV, LVESV, LVMI and Gensini score of STEMI complications in AAV group.
A. Correlation between mCRP and BNP. The plasma levels of mCRP were positively correlated with BNP ($r=0.349$, $P=0.034$). BNP, brain natriuretic peptide.

B. Correlation of mCRP and EF%. The plasma levels of mCRP were negatively correlated with EF% ($r=-0.362$, $P=0.027$). EF%, ejection fraction.

C. Correlation between mCRP and LVEDV. The plasma levels of mCRP were positively correlated with LVEVD ($r=0.375$, $P=0.022$). LVEDV, left ventricular end-diastolic volume.

D. Correlation between mCRP and LVESV. The plasma levels of mCRP were positively correlated with LVESV ($r=0.334$, $P=0.043$). LVESV, left ventricular end-systolic volume.

E. Correlation between mCRP and LVMI. The plasma levels of mCRP were positively correlated with LVMI ($r=0.736$, $P<0.001$). LVMI, left ventricular mass index.

F. Correlation between mCRP and Gensini score. The plasma levels of mCRP were positively correlated with Gensini score of STEMI complications in AAV group ($r=0.977$, $P=0.02$). STEMI, ST-segment elevation myocardial infarction.
| General clinical data                                      |       |
|-----------------------------------------------------------|-------|
| Subjects, n                                               | 37    |
| Gender male (n)/female (n)                                | 20/17 |
| Age, years old                                           | 58.5 ± 10.6 |
| Scr (μmol/L)                                              | 291.0 (161.5, 434.5) |
| Hb (g/L)                                                  | 107.5 ± 26.2 |
| ESR (mm/h)                                                | 46.0 (16.0, 88.0) |
| ALB (g/L)                                                 | 35.3 ± 8.9 |
| PTH (pg/mL)                                               | 54.8 (24.1, 80.0) |
| Uric acid (mmol/L)                                        | 375.6 ± 126.7 |
| Urinary protein 24h (g/24h)                              | 2.1 (1.3, 3.5) |
| CTnT (ng/mL)                                              | 0.049 (0.024, 0.068) |
| CK (U/L)                                                  | 30.0 (16.0, 50.0) |
| CK-MB (U/L)                                               | 11.0 (6.5, 17.0) |
| HDL-C (mmol/L)                                            | 1.34 (1.0, 1.7) |
| Tch (mmol/L)                                              | 5.2 (4.2, 6.3) |
| TG (mmol/L)                                               | 1.6 (1.0, 2.4) |
| LDL-C (mmol/L)                                            | 3.2 (2.8, 3.8) |

Abbreviation: Scr, Serum creatinine; Hb, Hemoglobin; PTH, Parathyroid hormone; CTnT, Cardiac troponin T; CK, Creatine kinase; CK-MB, Creatine kinase isoenzyme; HDL-C, high-density lipoprotein; Tch, Total serum cholesterol; TG, Triglyceride; LDL-C, Low-density lipoprotein.
Table 2: Compared the relationship between clinical indicators of cardiovascular risk factors in AAV.

| Risk factors for cardiovascular disease | mCRP | r   | P   |
|----------------------------------------|------|-----|-----|
| Modifiable cardiovascular risk factors  |      |     |     |
| 1 Lipid-related factors                 |      |     |     |
| TG                                     | -0.592 | <0.001 |
| Tch                                    | 0.083 | 0.623 |
| LDL-C                                  | 0.173 | 0.305 |
| HDL-C                                  | -0.055 | 0.748 |
| 2 Inflammation related factors          |      |     |     |
| CRP                                    | -0.340 | 0.040 |
| Fib                                    | -0.110 | 0.515 |

Abbreviations: Triglyceride, TG; Total cholesterol, Tch; Low-density Lipoprotein, LDL-C; High-Density Lipoprotein, HDL-C; C Reactive protein, CRP; Fibrinogen, Fib;
Table 3. Comparison mCRP and CRP with BNP, EF%, LVEDV, LVESV, LVMI and Gensini score with STEMI complications

| Parameters     | mCRP |       |       | CRP  |       |       |
|----------------|------|-------|-------|------|-------|-------|
|                | r    | P     |       | r    | P     |       |
| BNP            | 0.349| 0.034 |       | -0.360| 0.832 |       |
| EF%            | -0.362| 0.027 |       | 0.224 | 0.182 |       |
| LVEDV          | 0.375| 0.022 |       | -0.269| 0.108 |       |
| LVESV          | 0.334| 0.043 |       | -0.096| 0.571 |       |
| LVMI           | 0.736| p<0.001 |     | 0.001 | 0.996 |       |
| Gensini score  | 0.977| 0.023 |       | -0.730| 0.270 |       |

Abbreviations:  Brain natriuretic peptide, BNP; Echocardiography: ejection fraction, EF%;  
Left ventricular end-diastolic volume, LVEDV; Left ventricular end-systolic volume, LVESV;  
Left ventricular mass index, LVMI;